Przemysław B Radwański1, Steven Poelzing. 1. Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, 95 South 2000 East, Salt Lake City, UT 84112-5000, USA.
Abstract
AIMS: Andersen-Tawil syndrome (ATS1)-associated ventricular arrhythmias are initiated by premature ventricular activity (PVA) resulting from diastolic Ca(2+) (Ca(D)) accumulation. We hypothesized that relatively high Na(+)-Ca(2+) exchanger (NCX) expression coupled with slower Ca(2+) uptake may constitute an arrhythmogenic substrate during drug-induced ATS1 (DI-ATS1). METHODS AND RESULTS: DI-ATS1 was induced with 10 µmol/L BaCl(2) and 2 mmol/L [K(+)](o). Ca(2+) transients and action potentials were optically mapped from Langendorff-perfused guinea pig ventricles. Intracellular Ca(2+) handling was modulated by either direct NCX inhibition with 5 µmol/L KB-R7943 or by sarcoplasmic reticulum Ca(2+)-ATPase (SERCA2a) inhibition with cyclopiazonic acid (CPA). During DI-ATS1, PVA was more frequent in left ventricular (LV)-base (LVB) vs. LV-apex (LVA) (2.2 ± 0.8 vs. 0.6 ± 0.3 PVA/10 min), consistent with greater Ca(D) (1.65 ± 0.13 vs. 1.42 ± 0.09 normalized-Ca(D) units) and western blot-assessed NCX protein expression (81.2 ± 30.9%) in LVB relative to LVA. Further, regions of high NCX (LVB) evidenced a shorter PVA coupling interval relative to regions of low NCX expression (LVA, 67.7 ± 3.5 vs. 78.5 ± 3.6%). Inhibiting NCX during DI-ATS1 lowered the incidence of ventricular tachycardias (VTs, 0 vs. 25%) and PVA (1.5 ± 0.4 vs. 4.3 ± 1.4 PVA/10 min), but it did not affect PVA coupling intervals in LVB nor LVA (70.8 ± 4.3 vs. 73.8 ± 2.5%). Conversely, inhibition of SERCA2a with CPA, thereby increasing the role of NCX in Ca(2+) handling, significantly increased the incidence of VTs and PVA relative to DI-ATS1 alone, while decreasing the PVA coupling interval in all regions. CONCLUSION: PVA preferentially occurs in regions of enhanced NCX expression with relatively slower Ca(2+) uptake and during perfusion of CPA which further reduces sarcoplasmic reticular Ca(2+) uptake.
AIMS: Andersen-Tawil syndrome (ATS1)-associated ventricular arrhythmias are initiated by premature ventricular activity (PVA) resulting from diastolic Ca(2+) (Ca(D)) accumulation. We hypothesized that relatively high Na(+)-Ca(2+) exchanger (NCX) expression coupled with slower Ca(2+) uptake may constitute an arrhythmogenic substrate during drug-induced ATS1 (DI-ATS1). METHODS AND RESULTS: DI-ATS1 was induced with 10 µmol/L BaCl(2) and 2 mmol/L [K(+)](o). Ca(2+) transients and action potentials were optically mapped from Langendorff-perfused guinea pig ventricles. Intracellular Ca(2+) handling was modulated by either direct NCX inhibition with 5 µmol/L KB-R7943 or by sarcoplasmic reticulum Ca(2+)-ATPase (SERCA2a) inhibition with cyclopiazonic acid (CPA). During DI-ATS1, PVA was more frequent in left ventricular (LV)-base (LVB) vs. LV-apex (LVA) (2.2 ± 0.8 vs. 0.6 ± 0.3 PVA/10 min), consistent with greater Ca(D) (1.65 ± 0.13 vs. 1.42 ± 0.09 normalized-Ca(D) units) and western blot-assessed NCX protein expression (81.2 ± 30.9%) in LVB relative to LVA. Further, regions of high NCX (LVB) evidenced a shorter PVA coupling interval relative to regions of low NCX expression (LVA, 67.7 ± 3.5 vs. 78.5 ± 3.6%). Inhibiting NCX during DI-ATS1 lowered the incidence of ventricular tachycardias (VTs, 0 vs. 25%) and PVA (1.5 ± 0.4 vs. 4.3 ± 1.4 PVA/10 min), but it did not affect PVA coupling intervals in LVB nor LVA (70.8 ± 4.3 vs. 73.8 ± 2.5%). Conversely, inhibition of SERCA2a with CPA, thereby increasing the role of NCX in Ca(2+) handling, significantly increased the incidence of VTs and PVA relative to DI-ATS1 alone, while decreasing the PVA coupling interval in all regions. CONCLUSION: PVA preferentially occurs in regions of enhanced NCX expression with relatively slower Ca(2+) uptake and during perfusion of CPA which further reduces sarcoplasmic reticular Ca(2+) uptake.
Authors: Antonis A Armoundas; Ion A Hobai; Gordon F Tomaselli; Raimond L Winslow; Brian O'Rourke Journal: Circ Res Date: 2003-06-12 Impact factor: 17.367
Authors: Martin Tristani-Firouzi; Judy L Jensen; Matthew R Donaldson; Valeria Sansone; Giovanni Meola; Angelika Hahn; Said Bendahhou; Hubert Kwiecinski; Anna Fidzianska; Nikki Plaster; Ying-Hui Fu; Louis J Ptacek; Rabi Tawil Journal: J Clin Invest Date: 2002-08 Impact factor: 14.808
Authors: Mohammad T Elnakish; Benjamin D Canan; Ahmet Kilic; Peter J Mohler; Paul M L Janssen Journal: Pharmacol Res Date: 2016-11-30 Impact factor: 7.658
Authors: Lucia Brunello; Jessica L Slabaugh; Przemyslaw B Radwanski; Hsiang-Ting Ho; Andriy E Belevych; Qing Lou; Haiyan Chen; Carlo Napolitano; Francesco Lodola; Silvia G Priori; Vadim V Fedorov; Pompeo Volpe; Michael Fill; Paul M L Janssen; Sándor Györke Journal: Proc Natl Acad Sci U S A Date: 2013-06-03 Impact factor: 11.205
Authors: Megan Koleske; Ingrid Bonilla; Justin Thomas; Naveed Zaman; Stephen Baine; Bjorn C Knollmann; Rengasayee Veeraraghavan; Sándor Györke; Przemysław B Radwański Journal: J Gen Physiol Date: 2018-05-23 Impact factor: 4.086
Authors: Przemysław B Radwański; Christopher N Johnson; Sándor Györke; Rengasayee Veeraraghavan Journal: Front Physiol Date: 2018-09-04 Impact factor: 4.566
Authors: Mark A Munger; Yusuf Olğar; Megan L Koleske; Heather L Struckman; Jessica Mandrioli; Qing Lou; Ingrid Bonila; Kibum Kim; Roberto Ramos Mondragon; Silvia G Priori; Pompeo Volpe; Héctor H Valdivia; Joseph Biskupiak; Cynthia A Carnes; Rengasayee Veeraraghavan; Sándor Györke; Przemysław B Radwański Journal: J Am Heart Assoc Date: 2020-05-29 Impact factor: 5.501